TY - JOUR
T1 - Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor
AU - Yan, Hao
AU - Wu, Mengyao
AU - Yuan, Yan
AU - Wang, Zack Z.
AU - Jiang, Hua
AU - Chen, Tong
N1 - Funding Information:
This study was supported by the National Basic Research Program of China ( 2011CB910404 to T.C.), National Natural Science Foundation of China ( 31371480 to T.C.) and Foundation from Science and Technology Commission of Shanghai Municipality ( 13JC1406404 to T.C., 11JC1401501 and 12410710100 to H.J.).
PY - 2014/5/30
Y1 - 2014/5/30
N2 - Mesenchymal stem cells (MSCs) can be polarized into two distinct populations, MSC1 and MSC2, by activation of different Toll-like receptors (TLRs). TLR4-primed MSC1 expressed proinflammatory factors, whereas TLR3-primed MSC2 expressed suppressive factors. However, little is known about the function of TLRs on B lymphocyte-related immune modulation. In this study, we investigated the expression of B cell activating factor (BAFF), a member of the tumor necrosis factor ligand superfamily with notable stimulating activity on B cells, in human MSCs (hMSCs) and in murine MSCs (mMSCs) after activation of TLRs. BAFF was increasingly expressed in presence of TLR4 agonist (lipopolysaccharide, LPS), while TLR2 agonist (Zymosan) and TLR3-agonist (polyinocinic-polycytidykic acid, poly I:C) had no effect on BAFF expression. In addition, we demonstrated that signaling pathways of NF-κB, p38 MAPK, and JNK were involved in TLR4-primed BAFF expression. Our results suggested that TLR4 and downstream pathways in MSCs exert an important function in B lymphocyte-related immune regulation. Further defining a homogeneous population of MSCs should provide insight into MSC-based immune-modulating therapy.
AB - Mesenchymal stem cells (MSCs) can be polarized into two distinct populations, MSC1 and MSC2, by activation of different Toll-like receptors (TLRs). TLR4-primed MSC1 expressed proinflammatory factors, whereas TLR3-primed MSC2 expressed suppressive factors. However, little is known about the function of TLRs on B lymphocyte-related immune modulation. In this study, we investigated the expression of B cell activating factor (BAFF), a member of the tumor necrosis factor ligand superfamily with notable stimulating activity on B cells, in human MSCs (hMSCs) and in murine MSCs (mMSCs) after activation of TLRs. BAFF was increasingly expressed in presence of TLR4 agonist (lipopolysaccharide, LPS), while TLR2 agonist (Zymosan) and TLR3-agonist (polyinocinic-polycytidykic acid, poly I:C) had no effect on BAFF expression. In addition, we demonstrated that signaling pathways of NF-κB, p38 MAPK, and JNK were involved in TLR4-primed BAFF expression. Our results suggested that TLR4 and downstream pathways in MSCs exert an important function in B lymphocyte-related immune regulation. Further defining a homogeneous population of MSCs should provide insight into MSC-based immune-modulating therapy.
KW - BAFF
KW - LPS
KW - Mesenchymal stem cell
KW - Pro-inflammatory
KW - TLR4
UR - http://www.scopus.com/inward/record.url?scp=84901589224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901589224&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2014.04.097
DO - 10.1016/j.bbrc.2014.04.097
M3 - Article
C2 - 24780395
AN - SCOPUS:84901589224
SN - 0006-291X
VL - 448
SP - 212
EP - 217
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -